VCH-916

HCV NS5B polymerase inhibitor CAS# 1200133-34-1

VCH-916

Catalog No. BCC2031----Order now to get a substantial discount!

Product Name & Size Price Stock
VCH-916: 5mg $276 In Stock
VCH-916: 10mg Please Inquire In Stock
VCH-916: 20mg Please Inquire Please Inquire
VCH-916: 50mg Please Inquire Please Inquire
VCH-916: 100mg Please Inquire Please Inquire
VCH-916: 200mg Please Inquire Please Inquire
VCH-916: 500mg Please Inquire Please Inquire
VCH-916: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of VCH-916

Number of papers citing our products

Chemical structure

VCH-916

3D structure

Chemical Properties of VCH-916

Cas No. 1200133-34-1 SDF Download SDF
PubChem ID 46930992 Appearance Powder
Formula C26H36KNO4S M.Wt 497.73
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : ≥ 39 mg/mL (78.36 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name potassium;5-(cyclohexen-1-yl)-3-[(4-methoxycyclohexyl)-(4-methylcyclohexanecarbonyl)amino]thiophene-2-carboxylate
SMILES CC1CCC(CC1)C(=O)N(C2CCC(CC2)OC)C3=C(SC(=C3)C4=CCCCC4)C(=O)[O-].[K+]
Standard InChIKey RYXIBQLRUHDYEE-UHFFFAOYSA-M
Standard InChI InChI=1S/C26H37NO4S.K/c1-17-8-10-19(11-9-17)25(28)27(20-12-14-21(31-2)15-13-20)22-16-23(32-24(22)26(29)30)18-6-4-3-5-7-18;/h6,16-17,19-21H,3-5,7-15H2,1-2H3,(H,29,30);/q;+1/p-1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of VCH-916

DescriptionVCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor. IC50 Value: Target: HCV VCH-916 is a novel allosteric inhibitor of HCV NS5B polymerase. The RNA-dependent RNA polymerase (NS5B) of HCV is one of the attractive validated targets for development of new drugs to block HCV infection. VCH-916 is currently being evaluated for safety/tolerability, pharmacokinetics and anti-viral efficacy in chronically infected HCV patient.

References:
[1]. Ludmila Gerber, Tania M. Welzel, Stefan Zeuzem. New therapeutic strategies in HCV: polymerase inhibitors. Liver International. 2013,33(s1): 85-92 [2]. Abdelrahman S. Mayhoub. Hepatitis C RNA-dependent RNA polymerase inhibitors: A review of structure-activity and resistance relationships; different scaffolds and mutations. Bioorganic & Medicinal Chemistry. 2012, 20 (10): 3150-3161. [3]. Debasis Dasa, Jian Honga, Shu-Hui Chena, et al. Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors. Bioorganic & Medicinal Chemistry. 2011, 19(16): 4690-4703 [4]. Pierre L Beaulieu. Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection. Informahealthcare. 2009, 19(2): 145-164 [5]. Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection

VCH-916 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

VCH-916 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of VCH-916

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.0091 mL 10.0456 mL 20.0912 mL 40.1824 mL 50.228 mL
5 mM 0.4018 mL 2.0091 mL 4.0182 mL 8.0365 mL 10.0456 mL
10 mM 0.2009 mL 1.0046 mL 2.0091 mL 4.0182 mL 5.0228 mL
50 mM 0.0402 mL 0.2009 mL 0.4018 mL 0.8036 mL 1.0046 mL
100 mM 0.0201 mL 0.1005 mL 0.2009 mL 0.4018 mL 0.5023 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on VCH-916

VCH-916 is a novel allosteric inhibitor of HCV NS5B polymerase. The RNA-dependent RNA polymerase (NS5B) of HCV is one of the attractive validated targets for development of new drugs to block HCV infection. VCH-916 is currently being evaluated for safety/tolerability, pharmacokinetics and anti-viral efficacy in chronically infected HCV patient.

Featured Products
New Products
 

References on VCH-916

Current race in the development of DAAs (direct-acting antivirals) against HCV.[Pubmed:24735613]

Biochem Pharmacol. 2014 Jun 15;89(4):441-52.

The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C fall into four categories: (i) NS3/4A protease inhibitors: ABT-450/r, faldaprevir, asunaprevir, GS-9256, vedroprevir (GS-9451), danoprevir, MK-5172, vaniprevir, sovaprevir, ACH-2684, narlaprevir and simeprevir, in addition to those that are already developed [telaprevir (Incivek(R)) and boceprevir (Victrelis(R))], (ii) NS5A protein inhibitors: ABT-267, daclatasvir, ledipasvir, ACH-2928, ACH-3102, PPI-668, AZD-7295, MK-8742, and GSK 2336805; (iii) NS5B (nucleoside-type) polymerase inhibitors: sofosbuvir (now approved by the FDA since 6 December 2013), GS-0938, mericitabine, VX-135, ALS 2158 and TMC 649128; (iv) NS5B (non-nucleoside-type) polymerase inhibitors: VX-222, ABT-072, ABT-333, deleobuvir, tegobuvir, setrobuvir, VCH-916, VCH-759, BMS-791325 and TMC-647055. Future drug combinations will likely exist of two or more DAAs belonging to any of the 4 categories, with the aim to achieve (i) pan-genotypic hepatitis C virus (HCV) activity, (ii) little or no risk for resistance; (iii) short duration (i.e. 12 weeks) of treatment, and (iv) a sustained viral response (SVR) and definite cure of the disease.

Description

VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor.

Keywords:

VCH-916,1200133-34-1,Natural Products,HCV, buy VCH-916 , VCH-916 supplier , purchase VCH-916 , VCH-916 cost , VCH-916 manufacturer , order VCH-916 , high purity VCH-916

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: